Evidence for cervical cancer mortality with screening program in Taiwan, 1981–2010: age-period-cohort model

BMC Public Health

Yung-Po Liaw³  Chien-Chang Ho¹  Jing-Yang Huang³  Shih-Yung Su² 

[1] Department of Health and Leisure Management, Yuanpei University, Hsinchu City, 30015, Taiwan;Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Rm. 536, No. 17, Xuzhou Rd, Taipei 100, Taiwan;Department of Public Health and Institute of Public Health, Chung Shan Medical University, No. 110 Sec 1 Chien-Kuo N. Road, Taichung City 40201, Taiwan

关键词: Screening program;    Gynecologic oncology;    Mortality;    Age-period-cohort model;    Cervical cancer;   

Others  :  1162666
DOI  :  10.1186/1471-2458-13-13

 received in 2012-05-16, accepted in 2013-01-07,  发布年份 2013

【 摘 要 】

Background

Cervical cancer is the most common cancer experienced by women worldwide; however, screening techniques are very effective for reducing the risk of death. The national cervical cancer screening program was implemented in Taiwan in 1995. The objective of this study was to examine and provide evidence of the cervical cancer mortality trends for the periods before and after the screening program was implemented.

Methods

Data from 1981 to 2010 of the causes of death registered were obtained from the Department of Health, Taiwan. Age-standardized mortality rates, age-specific rates, and age-period-cohort models that employed the sequential method were used to assess temporal changes that occurred between 1981 and 2010, with 1995 used as the separating year.

Results

The results showed that for both time periods of 1981 to 1995 and 1996 to 2010, age and period had significant effects, whereas the birth cohort effects were insignificant. For patients between 80 and 84 years of age, the mortality rate for 1981 to 1995 and 1996 to 2010 was 48.34 and 68.08. The cervical cancer mortality rate for 1996 to 2010 was 1.0 for patients between 75 and 79 years of age and 1.4 for patients between 80 and 84 years of age compared to that for 1981 to 1995. Regarding the period effect, the mortality trend decreased 2-fold from 1996 to 2010.

Conclusions

The results of this study indicate a decline in cervical cancer mortality trends after the screening program involving Papanicolaou tests was implemented in 1995. However, the positive effects of the screening program were not observed in elderly women because of treatment delays during the initial implementation of the screening program.

【 授权许可】

   
2013 Su et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Vinh-Hung V, Bourgain C, Vlastos G, Cserni G, De Ridder M, Storme G, Vlastos AT: Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer 2007, 7:164. BioMed Central Full Text
• [2]Lau HY, Juang CM, Chen YJ, Twu NF, Yen MS, Chao KC: Aggressive characteristics of cervical cancer in young women in Taiwan. Int J Gynaecol Obstet 2009, 107(3):220-223.
• [3]Taylor R, Morrell S, Mamoon H, Wain G, Ross J: Decline in cervical cancer incidence and mortality in New South Wales in relation to control activities (Australia). Cancer Causes Control 2006, 17(3):299-306.
• [4]Sigurdsson K: Effect of organized screening on the risk of cervical cancer. Evaluation of screening activity in Iceland, 1964–1991. Int J Cancer 1993, 54:563-570.
• [5]Day NE: Effect of cervical cancer screening in Scandinavia. Obstet Gynecol 1984, 63(5):714-718.
• [6]Hakama M, Louhivuori K: A screening programme for cervical cancer that worked. Cancer Surv 1988, 7(3):403-416.
• [7]Nygard JF, Skare GB, Thoresen SO: The cervical cancer screening programme in Norway, 1992–2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen 2002, 9(2):86-91.
• [8]Patnick J: Cervical cancer screening in England. Eur J Cancer 2000, 36(17):2205-2208.
• [9]Schaffer P, Sancho-Garnier H, Fender M, Dellenbach P, Carbillet JP, Monnet E, Gauthier GP, Garnier A: Cervical cancer screening in France. Eur J Cancer 2000, 36(17):2215-2220.
• [10]Siebert U, Sroczynski G, Hillemanns P, Engel J, Stabenow R, Stegmaier C, Voigt K, Gibis B, Holzel D, Goldie SJ: The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur J Public Health 2006, 16(2):185-192.
• [11]Armour BS, Thierry JM, Wolf LA: State-level differences in breast and cervical cancer screening by disability status: United States, 2008. Womens Health Issues 2009, 19(6):406-414.
• [12]Latif E: Recent immigrants and the use of cervical cancer screening test in Canada. J Immigr Minor Health 2010, 12(1):1-17.
• [13]Wang PD, Lin RS: Epidemiology of cervical cancer in Taiwan. Gynecol Oncol 1996, 62(3):344-352.
• [14]Carstensen B: Age-period-cohort models for the Lexis diagram. Stat Med 2007, 26(15):3018-3045.
• [15]Chen YY, You SL, Chen CA, Shih LY, Koong SL, Chao KY, Hsiao ML, Hsieh CY, Chen CJ: Effectiveness of national cervical cancer screening programme in Taiwan: 12-year experiences. Br J Cancer 2009, 101(1):174-177.
• [16]Koong SL, Yen AM, Chen TH: Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. J Med Screen 2006, 13(Suppl 1):S44-S47.
• [17]Chang JI, Ou CH, Wu KM, Chen CC, Cheng KC: The evaluation of cervical cancer screening by combining speculoscopy with Papanicolaou smear examination in Taiwan. Zhonghua Yi Xue Za Zhi (Taipei) 2002, 65(9):430-434.
• [18]Chen LS, Huang N, Tsay JH, Wang PJ, Chou YJ, Chou P, Lee CH: Screening for cervical cancer among female physicians and their relatives in Taiwan: a population-based comparative study. Prev Med 2007, 44(6):531-535.
• [19]Louie KS, de Sanjose S, Diaz M, Castellsague X, Herrero R, Meijer CJ, Shah K, Franceschi S, Munoz N, Bosch FX: Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer 2009, 100(7):1191-1197.
• [20]Bosch FX, Munoz N, de Sanjose S, Izarzugaza I, Gili M, Viladiu P, Tormo MJ, Moreo P, Ascunce N, Gonzalez LC, et al.: Risk factors for cervical cancer in Colombia and Spain. Int J Cancer 1992, 52(5):750-758.
• [21]Hildesheim A, Herrero R, Castle PE, Wacholder S, Bratti MC, Sherman ME, Lorincz AT, Burk RD, Morales J, Rodriguez AC, et al.: HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 2001, 84(9):1219-1226.
• [22]Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, Shah KV, Meijer CJ, Bosch FX: Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case–control study. Lancet 2002, 359(9312):1093-1101.
• [23]Walter LC, Lewis CL, Barton MB: Screening for colorectal, breast, and cervical cancer in the elderly: a review of the evidence. Am J Med 2005, 118(10):1078-1086.
• [24]Baay MF, Smits E, Tjalma WA, Lardon F, Weyler J, Van Royen P, Van Marck EA, Vermorken JB: Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women. Int J Cancer 2004, 108(2):258-261.
• [25]Lichtman SM: Geriatric oncology: cervical cancer screening in elderly women. N Y State J Med 1991, 91(4):147-149.
• [26]Lewis LS: Screening for cervical cancer in elderly women. Lancet 1990, 335(8685):357.
• [27]Fahs MC, Mandelblatt J, Schechter C, Muller C: Cost effectiveness of cervical cancer screening for the elderly. Ann Intern Med 1992, 117(6):520-527.
• [28]Llorca J, Rodriguez-Cundin P, Dierssen-Sotos T, Prieto-Salceda D: Cervical cancer mortality is increasing in Spanish women younger than 50. Cancer Lett 2006, 240(1):36-40.
• [29]Cuzick J, Boyle P: Trends in cervix cancer mortality. Cancer Surv 1988, 7(3):417-439.
• [30]Beral V, Hermon C, Munoz N, Devesa SS: Cervical cancer. Cancer Surv 1994, 19–20:265-285.
• [31]Levi F, Lucchini F, Negri E, Franceschi S, la Vecchia C: Cervical cancer mortality in young women in Europe: patterns and trends. Eur J Cancer 2000, 36(17):2266-2271. 14. Lu TH
• [32]Lee MC, Chou MC: Accuracy of cause-of-death coding in Taiwan: types of miscoding and effects on mortality statistics. Int J Epidemiol 2000, 29(2):336-343.